A New Flow Cytometry-Based Single Platform for Universal and Differential Serodiagnosis of HTLV-1/2 Infection

In the present work, we developed and evaluated the performance of a new flow cytometry-based single platform, referred to as "FC-Duplex IgG1 (HTLV-1/2)", for universal and differential serodiagnosis of HTLV-1/2 infection. The proposed technology employs a system for detection of IgG1 antibodies in a single competitive immunofluorescence platform by flow cytometry using fluorescently labeled MT-2/MoT cell line mix coupled to a highly sensitive development system (Biotin/Streptavidin/Phycoerythrin). The stability of fluorescent labeling and the antigenicity of MT-2 and MoT cell lines were confirmed upon storage at -20°C for 2, 6, and 12 months. The anti-HTLV-1/2 IgG1 reactivity, expressed as percentage of positive fluorescent cells (PPFC), was evaluated for each target antigen along the titration curve of test serum samples (1:32 to 1:4,096). Upon selection of target cell line and serum dilutions with higher segregation score between groups, the performance of "FIX" and "FIX & PERM" protocols was evaluated. The "FIX" protocol presented excellent performance indices (Se = 92%/Sp = 94%/AUC = 0.96; Se = 96%/Sp = 100%/AUC = 0.99) for the universal (HTLV-1/2 vs. NI) and differential (HTLV-1 vs. HTLV-2) diagnosis of HTLV-1 infection, respectively. Optimization of the "FIX" protocol using the principle of synchronous and asynchronous pairwise analysis further improved the performance of "FC-Duplex IgG1 (HTLV-1/2)", using the "FIX" protocol for differential diagnosis of HTLV-1 and HTLV-2 infections (Se = 100%/Sp = 100%/AUC = 1.00). In conclusion, the "FC-Duplex IgG1 (HTLV-1/2)" method represents an innovation in the biotechnology segment with the potential to compose a serological kit for differential diagnosis of HTLV-1/2 infection for reference laboratories and blood centers.

Citing Articles

Performance of immunological assays for universal and differential diagnosis of HTLV-1/2 infection in candidates for blood donations from the Brazilian Amazon.

Santos F, Catao C, Martins J, Pessoa U, Sousa I, Melo J PLoS One. 2024; 19(7):e0298710.

PMID: 38968331 PMC: 11226060. DOI: 10.1371/journal.pone.0298710.

References

Teixeira-Carvalho A, Campos F, Geiger S, Rocha R, de Araujo F, Vitelli-Avelar D . FC-TRIPLEX Chagas/Leish IgG1: a multiplexed flow cytometry method for differential serological diagnosis of chagas disease and leishmaniasis. PLoS One. 2015; 10(4):e0122938. PMC: 4398351. DOI: 10.1371/journal.pone.0122938. View

Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A . HTLV-I associated myelopathy, a new clinical entity. Lancet. 1986; 1(8488):1031-2. DOI: 10.1016/s0140-6736(86)91298-5. View

da Silva Brito V, Santos F, Goncalves N, Araujo T, Nascimento D, Pereira F . Performance of Commercially Available Serological Screening Tests for Human T-Cell Lymphotropic Virus Infection in Brazil. J Clin Microbiol. 2018; 56(12). PMC: 6258847. DOI: 10.1128/JCM.00961-18. View

Miyoshi K, Kosaka M, Iguchi K, Umi M, Miyamoto H, Numata S . [B-lymphocyte leukemia. B-lymphocytosis and immunoglobulins]. Nihon Rinsho. 1981; 39(8):2806-14. View

Roucoux D, Murphy E . The epidemiology and disease outcomes of human T-lymphotropic virus type II. AIDS Rev. 2004; 6(3):144-54. View

Gallo R, Willems L, Hasegawa H . Screening transplant donors for HTLV-1 and -2. Blood. 2016; 128(26):3029-3031. DOI: 10.1182/blood-2016-09-739433. View

Martins M, da Silva Santos A, Namen-Lopes M, Figueiredo Barbosa-Stancioli E, Utsch D, Carneiro-Proietti A . Long-term serological follow-up of blood donors with an HTLV-indeterminate western blot: antibody profile of seroconverters and individuals with false reactions. J Med Virol. 2010; 82(10):1746-53. DOI: 10.1002/jmv.21881. View

Stramer S, Townsend R, Foster G, Johnson R, Weixlmann B, Dodd R . Discordant human T-lymphotropic virus screening with Western blot confirmation: evaluation of the dual-test algorithm for US blood donations. Transfusion. 2018; 58(3):638-640. DOI: 10.1111/trf.14471. View

Ji H, Chang L, Yan Y, Jiang X, Sun H, Guo F . A Strategy for Screening and Confirmation of HTLV-1/2 Infections in Low-Endemic Areas. Front Microbiol. 2020; 11:1151. PMC: 7283491. DOI: 10.3389/fmicb.2020.01151. View

10.

Kalyanaraman V, Sarngadharan M, Robert-Guroff M, Miyoshi I, Golde D, Gallo R . A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science. 1982; 218(4572):571-3. DOI: 10.1126/science.6981847. View

11.

Eusebio-Ponce E, Candel F, Anguita E . Human T-Cell Lymphotropic Virus Type 1 and associated diseases in Latin America. Trop Med Int Health. 2019; 24(8):934-953. DOI: 10.1111/tmi.13278. View

12.

Moreno C, Balangero M, Barbas M, Cudola A, Gallego S . [Serological diagnosis of HTLV-1/2: combination of screening assays to define the serological status in blood donors]. Rev Argent Microbiol. 2013; 45(3):165-8. DOI: 10.1016/s0325-7541(13)70019-1. View

13.

Castro-Costa C, Araujo A, Barreto M, Takayanagui O, Sohler M, da Silva E . Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). AIDS Res Hum Retroviruses. 2006; 22(10):931-5. DOI: 10.1089/aid.2006.22.931. View

14.

Gastaldello , GALLEGO , Isa , Nates , Medeot . Efficiency of indirect immunofluorescence assay as a confirmatory test for the diagnosis of human retrovirus infection (HIV-1 and HTLV-I/II) in different at risk populations. Rev Inst Med Trop Sao Paulo. 1999; 41(3):159-64. DOI: 10.1590/s0036-46651999000300005. View

15.

Martinez M, Al-Saleem J, Green P . Comparative virology of HTLV-1 and HTLV-2. Retrovirology. 2019; 16(1):21. PMC: 6686503. DOI: 10.1186/s12977-019-0483-0. View

16.

Mahieux R, Gessain A . HTLV-3/STLV-3 and HTLV-4 viruses: discovery, epidemiology, serology and molecular aspects. Viruses. 2011; 3(7):1074-90. PMC: 3185789. DOI: 10.3390/v3071074. View

17.

Ando Y, Ekuni Y, Matsumoto Y, Nakano S, Saito K, Kakimoto K . Long-term serological outcome of infants who received frozen-thawed milk from human T-lymphotropic virus type-I positive mothers. J Obstet Gynaecol Res. 2004; 30(6):436-8. DOI: 10.1111/j.1447-0756.2004.00227.x. View

18.

Osame M, Janssen R, Kubota H, Nishitani H, Igata A, Nagataki S . Nationwide survey of HTLV-I-associated myelopathy in Japan: association with blood transfusion. Ann Neurol. 1990; 28(1):50-6. DOI: 10.1002/ana.410280110. View

19.

Betters D . Use of Flow Cytometry in Clinical Practice. J Adv Pract Oncol. 2016; 6(5):435-40. PMC: 4803461. DOI: 10.6004/jadpro.2015.6.5.4. View

20.

Garcia L, Coelho-Dos-Reis J, Peruhype-Magalhaes V, Teixeira-Carvalho A, Rocha R, Araujo M . Anti-fixed Leishmania chagasi promastigotes IgG antibodies detected by flow cytometry (FC-AFPA-IgG) as a tool for serodiagnosis and for post-therapeutic cure assessment in American visceral leishmaniasis. J Immunol Methods. 2009; 350(1-2):36-45. DOI: 10.1016/j.jim.2009.07.004. View